معرفی
Dr. Cindy Shu is a Research Fellow at the University of Sydney, School of Medicine, with a focus on osteoarthritis (OA) and intervertebral disc degeneration. Her work spans musculoskeletal biology, inflammatory mechanisms, and stem cell therapy applications, often utilizing mouse and ovine models to explore disease pathogenesis and therapeutic interventions.
Dr. Shu's research delves into the biochemical and cellular changes in cartilage and disc tissues, including heparan sulfate and perlecan dynamics, matrix metalloproteinase activity, and immunomodulatory treatments. Her recent projects investigate systemic effects of OA, such as its link to cardiovascular disease via microRNA signaling, and disease-modifying therapies for comorbid conditions like chronic kidney disease and OA.
Analysis of her publications reveals trends in preclinical modeling of musculoskeletal disorders, synovial-immune interactions, and regenerative strategies involving growth factors and anti-inflammatory compounds. She has received recognition including the GRAMMER European Spine Journal Award 2020 and the MTP Connect REDI Fellowship (2021), supporting her work on IL12 pathway modulation in OA models.
Her collaborations with researchers like Christopher Little and James Melrose highlight interdisciplinary efforts in cartilage biology, disc regeneration, and multifidus muscle pathology. Grants from the National Health and Medical Research Council (NHMRC) and MTP Connect underscore her leadership in translating basic science to therapeutic innovations.
